Biologics Process Development & Characterization
Advancing robust, scalable biologics processes through scientific depth and operational precision, designed to eliminate rework and optimize COGS from day one.
Rapid execution
Platform-driven approaches and elimination of rework
Cost effective process characterization
Design of right-sized, phase-appropriate study plans for your molecule and modality
Economics by design
Development driven by a yield-first mindset, resulting in optimized COGS
“Our process development strategies are designed with future competitiveness in mind, optimizing yield and COGS early to secure long-term market advantage.”
When complexity stalls progress
- Black box approaches creating uncertainty
- Over/under-testing cost and compliance issues
- Methods without regulatory endpoints requiring rework
- Misaligned analytics causing delays and surprises
Clarity that drives progress
- Right-sized, tailored study plans
- CQA-focused assays that avoid over-testing
- Methods built with PPQ in mind from start
- Risk-aligned analytics that prevent rework
From molecule to commercial-scale GMP manufacturing
From early biologics development to commercial success, we deliver integrated process development solutions that minimize risk, accelerate timelines, and ensure scalability for biosimilar and NBE programs.
End-to-end Integration
Our integrated approach across upstream, downstream, and analytical development ensures seamless transfers, faster optimization, and regulatory-ready processes from early development through commercial delivery
Data-driven process optimization
Our QbD-and DoE-based strategies, applied across two complementary facilities and integrated PD teams, enable us to deliver tailored, scalable and cost-efficient processes, preventing late-stage surprises and accelerating your path to market
Seamless execution
Our two complementary facilities provide end-to-end continuity and reliable execution across all development phases, ensuring faster timelines, avoiding costly rework and reducing risks during tech transfer, scale up and PPQ
One dedicated team
With one cross-functional, expert team following your program from start to finish, you gain better alignment and smoother decision-making, preventing project delays in the later stages
Enabling upstream and downstream development from lab to GMP
Translating biosimilar and NBE molecules into robust, scalable, and regulatory-compliant biologics processes
Services
Services that speed progress and reduce risk
- Upstream process development
- Downstream process development
- Technology transfer
- Process scale-up up to 50L
- DoE- Process Characterization
- In-house analytical development
Key Technologies
Technologies that drive quality and efficiency
- Ambr® from Sartorius farm (15/250)
- 3-50L bioreactors
- ÄKTA™ from Cytiva
- Full in-house analytical development equipment
Where dedication
delivers capabilities
End-to-end European biologics CDMO delivering integrated process development, GMP manufacturing, and analytical services, faster and more cost-efficiently.
Analytical capabilities
Phase-appropriate, method-qualified testing for product quality and release
Read more
GMP manufacturing
Flexible capacity and inspection-ready operations for biologics production
Read more
Quality
Systems aligned with regulatory requirements, confirmed by successful inspections and focused on lifecycle aspects
Read more
Why biotechs and biopharmaceuticals
choose Rezon Bio
We combine the scale of an established European CDMO with the agility of a focused partner, backed by proven end-to-end biologics process development and manufacturing expertise.
Transparent. Clear. Reliable.
Partner with a European biologics CDMO dedicated to deliver program success
- Whether you’re advancing a novel biologic or planning for commercial scale, Rezon Bio is ready to help you move forward with confidence
- Connect with our team to explore how our expertise, integrated solutions, and dedication can accelerate your success